| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HON.708 |
| P698 | PubMed publication ID | 14594017 |
| P2860 | cites work | The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia | Q44369402 |
| Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas | Q44372685 | ||
| BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective | Q44372692 | ||
| 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia | Q44372696 | ||
| Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy | Q44372699 | ||
| Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit | Q44375010 | ||
| Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia | Q44375011 | ||
| Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial | Q44381570 | ||
| Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia | Q44381583 | ||
| Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia | Q44381586 | ||
| Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy | Q44383139 | ||
| Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma | Q44383154 | ||
| Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration | Q44383159 | ||
| High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma | Q44383236 | ||
| Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma | Q44386864 | ||
| Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation | Q44386867 | ||
| Recombinant urate oxidase (rasburicase): a new targeted therapy for prophylaxis and treatment of patients with hematologic malignancies at risk of tumor lysis syndrome | Q44388176 | ||
| Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation | Q44393016 | ||
| Thalidomide as initial therapy for early-stage myeloma | Q44394897 | ||
| Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies | Q44402715 | ||
| Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. | Q44405230 | ||
| Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors in Older Patients With Myeloid Leukemia | Q44405234 | ||
| Human Granulocyte Colony-Stimulating Factor in Children With High-Risk Acute Lymphoblastic Leukemia: A Children’s Cancer Group Study | Q44405259 | ||
| Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia | Q44422804 | ||
| Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group | Q44422817 | ||
| A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma. | Q44455479 | ||
| Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy | Q44455495 | ||
| ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphoma. | Q44475809 | ||
| Treatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximab | Q44475813 | ||
| CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas | Q44509203 | ||
| Thalidomide in relapsed or refractory multiple myeloma: how much and for how long? | Q44509206 | ||
| A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma | Q47614903 | ||
| Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation | Q47768001 | ||
| Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation | Q47839930 | ||
| CNS-Directed Therapy for Childhood Acute Lymphoblastic Leukemia: Childhood ALL Collaborative Group Overview of 43 Randomized Trials | Q47944694 | ||
| CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease | Q47999978 | ||
| Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. | Q51600795 | ||
| Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. | Q53938789 | ||
| Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. | Q53940865 | ||
| Lineage-specific chimaerism quantification after T-cell depleted peripheral blood stem cell transplantation. | Q54771181 | ||
| Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions. | Q54778735 | ||
| PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma. | Q54781462 | ||
| Prognostic significance of the TEL-AML1 fusion gene in pediatric acute lymphoblastic leukemia in Turkey. | Q54785742 | ||
| Residual leukaemia after bone marrow transplant in children with acute lymphoblastic leukaemia after first haematological relapse or with poor initial presenting features. | Q54789388 | ||
| Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. | Q54790089 | ||
| Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma | Q58050885 | ||
| Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial | Q58416185 | ||
| A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia | Q73005236 | ||
| Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials | Q73063060 | ||
| Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial | Q44315387 | ||
| Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias | Q44319713 | ||
| Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts | Q44319719 | ||
| Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up | Q44319724 | ||
| A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome | Q44323787 | ||
| Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias | Q44323790 | ||
| Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab | Q44325043 | ||
| Reduced-intensity bone marrow transplantation from an alternative unrelated donor for myelodysplastic syndrome of first-donor origin | Q44327943 | ||
| Extended follow-up of patients with hairy cell leukemia after treatment with cladribine | Q44333790 | ||
| Increased levels of immune transcript in patients with acute GVHD after allogeneic stem cell transplantation | Q44351289 | ||
| Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. | Q44351320 | ||
| Cytotoxic chemotherapy preceding apheresis of peripheral blood progenitor cells can affect the early reconstitution phase of naive T cells after autologous transplantation | Q44351351 | ||
| Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. | Q44356040 | ||
| Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes | Q44356043 | ||
| A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma | Q44357181 | ||
| Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved | Q44360452 | ||
| Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. | Q44362112 | ||
| Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients | Q44369393 | ||
| Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype | Q44369398 | ||
| Prognostic factors and outcome for children after second central nervous system relapse of acute lymphoblastic leukaemia | Q73072424 | ||
| Treatment of lymphoblastic lymphoma in adults | Q73080793 | ||
| Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission | Q73089003 | ||
| Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival | Q73089005 | ||
| Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow | Q73089048 | ||
| Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia | Q73152569 | ||
| Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma | Q73263669 | ||
| Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia | Q73267761 | ||
| Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM | Q73330861 | ||
| Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network | Q73330865 | ||
| Intensification of Therapy for Children With Lower-Risk Acute Lymphoblastic Leukemia: Long-Term Follow-Up of Patients Treated on Children’s Cancer Group Trial 1881 | Q73330878 | ||
| Adjusted conditioning for allogeneic transplantation in a single center setting: mixed chimerism heralds relapse | Q73441704 | ||
| Relative importance of CD38 expression over myeloid-associated markers expression in predicting the clinical course of B-CLL patients | Q73650017 | ||
| Autologus stem cell transplantation as postremission therapy for acute myeloid leukemia. Risk factors at diagnosis can predict the outcome | Q73650079 | ||
| In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression | Q78410148 | ||
| The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia | Q78447828 | ||
| Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia | Q78460516 | ||
| Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance | Q78556887 | ||
| Advances in the biology and treatment of myeloma bone disease | Q78769316 | ||
| Hematopoietic recovery after unrelated umbilical cord-blood allogeneic transplantation in adults treated with in vivo stem cell factor (R-MetHuSCF) and filgrastim administration | Q78825180 | ||
| Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen | Q78966941 | ||
| Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia | Q78966954 | ||
| Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia | Q28186429 | ||
| Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa | Q28191349 | ||
| Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. | Q33346486 | ||
| Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission | Q33346528 | ||
| A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. | Q33346607 | ||
| Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients | Q33346756 | ||
| Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma | Q33347071 | ||
| Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia | Q33347187 | ||
| 14-Day Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin’s Lymphoma: Results of a Pilot Study of the German Hodgkin’s Lymphoma Study Group | Q33347787 | ||
| Clinico-hematologic features of myelodysplastic syndrome presenting as isolated thrombocytopenia: an entity with a relatively favorable prognosis | Q33348183 | ||
| The Japanese cord blood bank network experience with cord blood transplantation from unrelated donors for haematological malignancies: an evaluation of graft-versus-host disease prophylaxis | Q33445489 | ||
| Analysis of 127 stem cell donations of the regional Bone Marrow Donor Bank Europdonor Nijmegen, The Netherlands | Q33445761 | ||
| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia | Q34183674 | ||
| Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia | Q34186569 | ||
| Anemia and epoetin alfa in high-dose chemotherapy programs for breast cancer patients | Q34705421 | ||
| Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma | Q35029568 | ||
| Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment | Q35035221 | ||
| Myeloma and the newly diagnosed patient: a focus on treatment and management | Q35042130 | ||
| High-dose therapy and immunomodulatory drugs in multiple myeloma | Q35042147 | ||
| Low-dose thalidomide in myeloma: efficacy and biologic significance | Q35042148 | ||
| The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review | Q35047863 | ||
| Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies | Q35062841 | ||
| Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience | Q35067047 | ||
| A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. | Q35068414 | ||
| Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries | Q35076617 | ||
| Acute lymphoblastic leukaemia: diagnosis and classification. | Q35078291 | ||
| Results of minimal residual disease (MRD) evaluation and MRD-based treatment stratification in childhood ALL. | Q35078294 | ||
| Risk-adapted treatment according to minimal residual disease in adult ALL. | Q35078296 | ||
| Stem cell transplantation in adult ALL patients | Q35078298 | ||
| Autologous stem cell transplantation and purging in adult acute lymphoblastic leukaemia | Q35078303 | ||
| Treatment of mature B-ALL and high grade B-NHL in children | Q35078305 | ||
| New treatment strategies in childhood acute lymphoblastic leukaemia | Q35078312 | ||
| Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia | Q35078315 | ||
| Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts. | Q35078317 | ||
| New agents in the treatment of acute lymphocytic leukaemia | Q35078321 | ||
| Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia | Q35084229 | ||
| Monitoring minimal residual disease in AML: the right time for real time | Q35084711 | ||
| The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia | Q35094049 | ||
| T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. | Q35094078 | ||
| Practical management of patients with chronic myeloid leukemia receiving imatinib | Q35095956 | ||
| Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). | Q35102183 | ||
| Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase | Q35102266 | ||
| Transformed lymphoma: an Achilles' heel of non-Hodgkin's lymphoma | Q35106138 | ||
| New approaches in the immunotherapy of haematological malignancies. | Q35106657 | ||
| Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation | Q35108004 | ||
| Monoclonal antibody therapy of chronic lymphocytic leukemia | Q35117268 | ||
| Novel Therapies in Multiple Myeloma | Q35121620 | ||
| Recent Developments in Hematopoietic Stem Cell Transplantation for Multiple Myeloma | Q35121623 | ||
| Immunosuppressive treatments for myelodysplastic syndromes | Q35137166 | ||
| Recent advances in the treatment of infant acute myeloid leukemia | Q35152603 | ||
| Predicting long-term survival in multiple myeloma patients following autotransplants | Q35152606 | ||
| Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome | Q35175273 | ||
| Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach | Q35175287 | ||
| Immunoglobulin gene rearrangement investigations in the diagnosis of lymphoid malignancies from formaldehyde-fixed biopsies | Q38452192 | ||
| Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma | Q40557017 | ||
| Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma | Q40563622 | ||
| Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. | Q40565158 | ||
| Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome | Q40604775 | ||
| Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). | Q43409102 | ||
| Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia | Q43633203 | ||
| Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation | Q44017116 | ||
| High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. | Q44198528 | ||
| Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies | Q44201555 | ||
| Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study | Q44232589 | ||
| Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. | Q44240279 | ||
| Non-T-cell-depleted HLA haploidentical stem cell transplantation in advanced hematologic malignancies based on the feto-maternal michrochimerism | Q44248058 | ||
| Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. | Q44253359 | ||
| High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. | Q44253362 | ||
| Stage I and II aggressive B-cell lymphomas of the head and neck: radiotherapy alone as a treatment option and the usefulness of the new prognostic index B-ALPS. | Q44263728 | ||
| Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol | Q44264204 | ||
| Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy | Q44265652 | ||
| Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia | Q44280528 | ||
| Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide | Q44280535 | ||
| A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia | Q44280538 | ||
| Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors | Q44284842 | ||
| A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma | Q44299819 | ||
| Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up | Q44299821 | ||
| Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma | Q44299823 | ||
| Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis | Q44304230 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 141-148 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | Hematological Oncology | Q15762617 |
| P1476 | title | Recent publications in hematological oncology | |
| P478 | volume | 21 |
Search more.